{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:33:38Z","timestamp":1784554418177,"version":"3.55.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Despite the application of antiviral drugs and improved surveillance tools, the number of patients diagnosed with hepatocellular carcinoma (HCC) at an advanced stage and with a dismal prognosis is still on the rise. Systemic treatment with multiple multitargeted tyrosine kinase inhibitors (TKIs), such as sorafenib, has been a widely utilized approach for a decade. In addition, the use of a combination of TKIs with other types of compounds, including immune checkpoint inhibitors (ICIs) and antiangiogenic inhibitors, has shown efficacy in treating advanced HCC. However, the presence of intolerable adverse events, low disease response and control rates, and relative short overall survival of such combinatory therapies makes novel or optimized therapies for advance HCC urgently needed. Locoregional therapy (transarterial chemoembolization, and thermal ablation) can destroy primary tumors and decrease tumor burden and is widely used for HCC management. This type of treatment modality can result in local hypoxia and increased vascular permeability, inducing immunogenic effects by releasing tumor antigens from dying cancer cells and producing damage-associated molecular patterns that facilitate antiangiogenic therapy and antitumor immunity. The combination of systemic and locoregional therapies may further produce synergistic effects without overlapping toxicity that can improve prognoses for advanced HCC. In preliminary studies, several combinations of therapeutic modes exhibited promising levels of safety, feasibility, and antitumor effects in a clinical setting and have, thus, garnered much attention. This review aims to provide a comprehensive, up-to-date overview of the underlying mechanisms of combined systemic and locoregional therapies in the treatment of advanced HCC, commenting on both their current status and future direction.<\/jats:p>","DOI":"10.3389\/fmolb.2021.635243","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:32:42Z","timestamp":1618295562000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development"],"prefix":"10.3389","volume":"8","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"B79","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jvir.2014.08.027","article-title":"Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update","volume":"273","author":"Ahmed","year":"2014","journal-title":"Radiology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1148\/radiol.10081634","article-title":"Principles of and advances in percutaneous ablation","volume":"258","author":"Ahmed","year":"2011","journal-title":"Radiology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12885-020-6519-y","article-title":"3D visualization ablation planning system assisted microwave ablation for hepatocellular carcinoma (Diameter >3): a precise clinical application","volume":"20","author":"An","year":"2020","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00270-012-0405-1","article-title":"A comparison of direct heating during radiofrequency and microwave ablation in ex vivo liver","volume":"36","author":"Andreano","year":"2013","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/00313020802579292","article-title":"A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver","volume":"41","author":"Bhardwaj","year":"2009","journal-title":"Pathology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/s-0032-1329906","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin. Liver Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000496439","article-title":"Systemic treatment for advanced hepatocellular carcinoma","volume":"8","author":"Bouattour","year":"2019","journal-title":"Liver Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"974514","DOI":"10.4061\/2011\/974514","article-title":"Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study","volume":"2011","author":"Bouchard-Fortier","year":"2011","journal-title":"Int. J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B38","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am. J. Pathol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2012","journal-title":"J. Hepatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/hep.22648","article-title":"Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies","volume":"49","author":"Cho","year":"2009","journal-title":"Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrc3672","article-title":"Thermal ablation of tumours: biological mechanisms and advances in therapy","volume":"14","author":"Chu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.cld.2020.07.012","article-title":"Tyrosine kinase inhibitors and hepatocellular carcinoma","volume":"24","author":"da Fonseca","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3760\/cma.j.issn.1007-3418.2020.02.004","article-title":"Commission of the people\u2019s republic of guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)","volume":"28","year":"2020","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B83","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2015.08.020","article-title":"Immunity, tolerance and autoimmunity in the liver: a comprehensive review","volume":"66","author":"Doherty","year":"2016","journal-title":"J. Autoimmun."},{"key":"B91","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/cco-20-113","article-title":"Hepatocellular carcinoma, novel therapies on the horizon","volume":"10","author":"El Dika","year":"2021","journal-title":"Chin. Clin. Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/1097-0142(19800201)45:3<613::aid-cncr2820450331>3.0.co;2-e","article-title":"Effects of hyperthermia in a malignant tumor","volume":"45","author":"Fajardo","year":"1980","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12072-020-10052-y","article-title":"Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases","volume":"14","author":"Fang","year":"2020","journal-title":"Hepatol. Int."},{"key":"B65","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fern\u00e1ndez","year":"2009","journal-title":"J. Hepatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/hep.31306","article-title":"Evolution of systemic therapy for hepatocellular carcinoma","volume":"73","author":"Finn","year":"2020","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1148\/radiol.12112264","article-title":"Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?","volume":"265","author":"Georgiades","year":"2012","journal-title":"Radiology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1148\/radiol.2015150667","article-title":"TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON","volume":"279","author":"Geschwind","year":"2016","journal-title":"Radiology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.14218\/JCTH.2020.00001","article-title":"Management and treatment of hepatocellular carcinoma with immunotherapy: a review of current and future options","volume":"8","author":"Ghavimi","year":"2020","journal-title":"J. Clin. Transl Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs. conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br. J. Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2217\/fon-2020-0162","article-title":"IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation","volume":"16","author":"Hack","year":"2020","journal-title":"Future Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.3748\/wjg.v21.i36.10327","article-title":"Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system","volume":"21","author":"Han","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jvir.2011.03.005","article-title":"Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort","volume":"22","author":"Hu","year":"2011","journal-title":"J. Vasc. Interv. Radiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00261-020-02426-5","article-title":"Computed tomography-guided radiofrequency ablation combined with transarterial embolization assisted by a three-dimensional visualization ablation planning system for hepatocellular carcinoma in challenging locations: a preliminary study","volume":"45","author":"Huang","year":"2020","journal-title":"Abdom. Radiol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune surveillance by the liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0184597","DOI":"10.1371\/journal.pone.0184597","article-title":"Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials","volume":"12","author":"Katsanos","year":"2017","journal-title":"PloS one"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2214\/ajr.175.6.1751665","article-title":"Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis","volume":"175","author":"Katyal","year":"2000","journal-title":"AJR Am. J. Roentgenol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/ajg.2014.152","article-title":"Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2\u00a0cm or smaller","volume":"109","author":"Kim","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00261-019-01952-1","article-title":"Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy","volume":"44","author":"Kim","year":"2019","journal-title":"Abdom. Radiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hep.31424","article-title":"Local and regional therapies for hepatocellular carcinoma","volume":"73","author":"Kloeckner","year":"2020","journal-title":"Hepatology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jvir.2015.04.030","article-title":"Watershed hepatocellular carcinomas: the risk of incomplete response following transhepatic arterial chemoembolization","volume":"26","author":"Kothary","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.crad.2012.06.112","article-title":"Hepatic embolotherapy in interventional oncology: technology, techniques, and applications","volume":"68","author":"Kritzinger","year":"2013","journal-title":"Clin. Radiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1159\/000439290","article-title":"Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified bolondi\u2019s subclassification (kinki criteria)","volume":"33","author":"Kudo","year":"2015","journal-title":"Dig. Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.4110\/in.2020.20.e11","article-title":"Current status and future direction of immunotherapy in hepatocellular carcinoma: what do the data suggest?","volume":"20","author":"Lee","year":"2020","journal-title":"Immune Netw."},{"key":"B69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib): second interim analysis","volume":"68","author":"Lencioni","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"B53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12876-018-0849-0","article-title":"Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"18","author":"Li","year":"2018","journal-title":"BMC Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"79742","DOI":"10.18632\/oncotarget.19275","article-title":"Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D \u2265 3\u00a0cm): preliminary results","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.4103\/jcrt.JCRT_380_19","article-title":"Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: a propensity score matching study","volume":"16","author":"Li","year":"","journal-title":"J. Cancer Res. Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4103\/jcrt.JCRT_910_18","article-title":"Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: \u201cA sharp sword\u201d","volume":"15","author":"Li","year":"2019","journal-title":"J. Cancer Res. Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4103\/jcrt.JCRT_850_20","article-title":"TATI modality: a new perspective on the treatment of advanced hepatocellular carcinoma","volume":"16","author":"Li","year":"","journal-title":"J. Cancer Res. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1148\/radiol.2351031944","article-title":"Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation","volume":"235","author":"Liang","year":"2005","journal-title":"Radiology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.3748\/wjg.v19.i33.5430","article-title":"Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy","volume":"19","author":"Liang","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4103\/jcrt.JCRT_101_20","article-title":"Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): a novel treatment for patients with advanced hepatocellular carcinoma","volume":"16","author":"Meng","year":"2020","journal-title":"J. Cancer Res. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"741","DOI":"10.4103\/jcrt.JCRT_400_19","article-title":"Apatinib for hepatocellular carcinoma","volume":"15","author":"Ni","year":"2019","journal-title":"J. Cancer Res. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jss.2005.02.009","article-title":"Mechanisms of focal heat destruction of liver tumors","volume":"127","author":"Nikfarjam","year":"2005","journal-title":"J. Surg. Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e000455","DOI":"10.1136\/esmoopen-2018-000455","article-title":"Immunotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"3","author":"Okusaka","year":"2018","journal-title":"ESMO Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2019.09.023","article-title":"Role of locoregional therapies in the wake of systemic therapy","volume":"72","author":"Palmer","year":"2020","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int."},{"key":"B64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4103\/ijri.IJRI_352_18","article-title":"Early experience of combination therapy of transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma measuring 3\u20137\u00a0cm","volume":"29","author":"Patidar","year":"2019","journal-title":"Indian J. Radiol. Imaging"},{"key":"B71","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1148\/radiol.2019181818","article-title":"Microvascular invasion as a predictor of response to treatment with sorafenib and transarterial chemoembolization for recurrent intermediate-stage hepatocellular carcinoma","volume":"292","author":"Peng","year":"2019","journal-title":"Radiology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cld.2020.07.011","article-title":"Locoregional therapies for hepatocellular carcinoma","volume":"24","author":"Pillai","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.4254\/wjh.v7.i8.1054","article-title":"Percutaneous microwave ablation vs. radiofrequency ablation in the treatment of hepatocellular carcinoma","volume":"7","author":"Poulou","year":"2015","journal-title":"World J. Hepatol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/JHC.S224938","article-title":"Combination antiangiogenic and immunotherapy for advanced hepatocellular carcinoma: evidence to date","volume":"7","author":"Raybould","year":"2020","journal-title":"J. Hepatocell. Carcinoma"},{"key":"B81","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"HEP20","DOI":"10.2217\/hep-2020-0004","article-title":"Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies","volume":"7","author":"Roderburg","year":"2020","journal-title":"Hepatic Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4756147","DOI":"10.1155\/2018\/4756147","article-title":"Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery","volume":"2018","author":"Shiina","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4103\/jcrt.JCRT_345_19","article-title":"Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: a propensity score matching analysis","volume":"16","author":"Shuanggang","year":"2020","journal-title":"J. Cancer Res. Ther."},{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"Ca. Cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J. Hepatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1586\/14737140.8.11.1743","article-title":"Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease","volume":"8","author":"Strebel","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma. reply","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/02841850801958890","article-title":"Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization","volume":"49","author":"Wang","year":"2008","journal-title":"Acta Radiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1245\/aso.2003.03.045","article-title":"Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis","volume":"10","author":"Wright","year":"2003","journal-title":"Ann. Surg. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s12885-017-3545-5","article-title":"The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B\/C hepatocellular carcinoma","volume":"17","author":"Wu","year":"2017","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights","volume":"9","author":"Xie","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"B98","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/jgh.12088","article-title":"Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy","volume":"28","author":"Xu","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/hep.22412","article-title":"Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis","volume":"48","author":"Yao","year":"2008","journal-title":"Hepatology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3892\/mco.2015.554","article-title":"Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma","volume":"3","author":"Yao","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/gutjnl-2016-312629","article-title":"Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial","volume":"66","author":"Yu","year":"2017","journal-title":"Gut"},{"key":"B85","doi-asserted-by":"publisher","first-page":"188441","DOI":"10.1016\/j.bbcan.2020.188441","article-title":"Immunotherapy for advanced hepatocellular carcinoma, where are we?","volume":"1874","author":"Zhang","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5152\/dir.2018.17528","article-title":"Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma","volume":"24","author":"Zhang","year":"2018","journal-title":"Diagn. Interv. Radiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000488035","article-title":"Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition)","volume":"7","author":"Zhou","year":"2018","journal-title":"Liver Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.635243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:32:45Z","timestamp":1618295565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.635243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":106,"alternative-id":["10.3389\/fmolb.2021.635243"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.635243","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"article-number":"635243"}}